How drugmakers should prepare for and respond to the forces poised to reshape the industry was a popular topic on day one of the 36th annual JP Morgan Healthcare Conference.
Shire considers splitting into two units; New Jersey finalizes physician-pharma gift limit; more biotech M&As expected in 2018
MM&M is calling for nominations for the 2018 class of Top 40 Healthcare Transformers and is seeking industry input for the Top 10 Innovation Catalysts.
Accenture will not consider a takeover bid for a large ad agency group because its chief executive says there has been a "100%" failure rate with such deals.
WPP has named Karen Blackett as its first UK country manager, making her the most important agency leader in the British ad industry.
Celgene to buy Impact Biomedicines for up to $7 billion; Pfizer plans to cut 300 positions in neuroscience; Perrigo hires new CEO
As HCPs continue to be stretched for time to diagnose and interact with patients, health bots could help reduce HCP workload and drive patient engagement.
Do the healthcare and pharma arms of Accenture, Deloitte, PwC, and other consultancies pose an existential threat to traditional healthcare agencies?
Takeda announces deals worth more than $1 billion; biotech and pharma investments reached $10.5 billion in 2017; prescriptions for nerve pain on the rise
Kevin Griffis brought his experience in government and politics to Planned Parenthood at the perfect time, leading the fight to protect birth control coverage under the Trump administration and destigmatizing abortion.
US bank JPMorgan Chase has returned to advertising on YouTube only after developing its own algorithm that ensures its ads are not placed around questionable content.
Allergan to cut 1,000 jobs; McKesson acquires RxCrossroads from CVS Health; Pfizer and Sangamo enter collaboration to develop ALS gene therapy
Utah Senator who backed Orphan Drug Act will not seek reelection; medicines more expensive in 2018; Spark's genetic therapy for rare blindness costs $850,000
The group's reports, received with great interest by insurers and the Department of Veteran Affairs, have concluded certain high-profile drugs aren't worth the cost. Pharma still hasn't decided whether ICER is friend or foe.
A sea change may be afoot in OTC, with multiple healthcare businesses in play. Could consumer goods companies fill the void left by big pharma?
FDA approvals hit a 21-year high; drug prices account for higher U.S. healthcare spend; industry enters 2018 amidst consolidation, uncertainty
Study: male docs earn more than female peers; new Michigan law tackles opioid crisis; study: some docs billed Medicare for most expensive patient visit type
Digital innovation in Japan, health-tech trends, and social media top the list.
The Department of Veteran Affairs issued an RFI at the end of November for a nationwide healthcare professional recruitment campaign.
Mallinckrodt to buy Sucampo for $1.2 billion; Amazon pushes digital advertising in 2018; WHO classifies gaming disorder as mental health condition
The agency issue, people moves, and a series of restructures top the list.
VP of investor relations Teri Loxam will take over Ambrose's role in January.
Roche to buy Ignyta for $1.7 billion; FDA OKs Valeant eye drop for OTC sale; Kmart settles prescription drug fraud allegations
Topping the list: The MM&M agency issue, the MM&M Awards winners and shortlist, and how a porn star is providing sex ed to seniors
BI to pay $13.5 million for misleading marketing; ICER: CAR-T therapies more cost-effective than chemotherapy; FDA approves Roche's breast cancer combo therapy
Cancer Research UK's 'Right Now' brand campaign will return in 2018 with a new focus highlighting the impact that research has on people suffering with cancer.
Beiser previously held leadership roles at Edelman, Hilton, Discover, and Burson-Marsteller.
Tax bill could lead pharma to move overseas; global pharma sales increased 45% in nine years; FDA OKs first gene therapy for rare retinal disease
Brands should refrain from tweets that are over 100 characters, according to Twitter's director of brand strategy.
The Every Try Counts campaign to change how smokers see their last attempt to quit.
Pharma industry spent $57 million on lobbying in 2016; Humana, private equity firms to buy Kindred for $4 billion; price of old glaucoma drug skyrockets
CVS/Aetna deal will affect healthcare benefits; lawmakers pressure DEA to curb painkiller supply; Allergan and Richter's Vraylar sees positive results for bipolar depression
The pharma unit of Johnson & Johnson launched the Cancer.com website this month.
Pharma R&D return on investment falls to eight-year low; FDA approves Pfizer's biosimilar to J&J's Remicade; Novartis to downsize generics business
FDA approves first topical skin growth treatment; Teva to cut 14,000 jobs; Novartis Oncology CEO resigns
The VP of market access at Mitsubishi Tanabe Pharma America discusses driving access and bringing to market the first FDA-approved ALS drug in years.
Teva diminishes debt with job cuts and sale; FDA to study whether consumers can detect misleading ads; AbbVie, Roche present positive Phase-III data at ASH
The drugmaker named William Huyett as COO and Gina Consylman as SVP and CFO.
The digital health startup was founded in 2015.
FDA issues prescription drug promotion guidance; FDA approves first follow-on biologic of Lilly's Humalog; drugmakers allegedly hired nurses to promote drugs
Whatever REDUCE-IT ultimately reveals (results from the completed study are expected in Q2 or Q3 2018), Salyer maintains Amarin has "a great story to tell, with or without the data."
GCI Health has confirmed new hire Kath Kerry and maternity leave returner Rikki Jones as co-MDs of its London operation, the network's second hub alongside its New York headquarters.
Pfizer's Viagra generic to sell for half the price; GSK seeks oncology deals; Ionis' experimental Huntington's drug tackles toxic protein for the first time
Drugmakers are proud of the patient service programs they've developed. Yet there remains a disconnect in the way information is communicated to HCPs.
A study has found that channels certified by the Trustworth Accountability Group (TAG) had 83% less ad fraud than the broader industry average.
Cannes Lions' longtime leader, chief spokesman, and a figure many viewed as the heart and soul of the global creativity festival will be moving on after the 2018 event ends.
FDA approves first nebulized LAMA COPD treatment; more than 2,000 cancer immunotherapies in development; FDA issues 3D-printing guidance
UnitedHealth Group to buy DaVita primary care unit for $4.9 billion; Roche drug combo doubles lung-cancer survival in trial; study: FDA programs expedite drug approval
DeVine will oversee the agency's health IT and medical device work.
Lighthouse received $50,000 for application aimed at providing more accessible and engaging care for those living with diabetes.
Next year will be the start of the shift from marketing algorithms to AI, predicts Kantar Millward Brown.
FDA approves Novo's diabetes drug; Walgreens undergoes rebranding in the wake of CVS-Aetna merger; pharma increasingly transparent about clinical trial data
Innovation-minded executives share their thoughts and predictions for the year ahead.
The first year of the Trump administration was kind to pharma, but it might not be so fortunate in 2018.
Botox-like wrinkle-reducer shows positive results in trials; investors double down on fertility; few websites transparent about pricing, study finds
GroupM, the media investment arm of WPP, forecasts global ad growth of 4.3% in 2018, and predicts Google and Facebook will strengthen their stranglehold on digital advertising.
Content Collective takes the Pixar film's creators on their own genealogy journeys.
CVS to buy Aetna for $69 billion; J&J buys commercial rights for biotech's experimental hypertension drug; Republicans repeal Obamacare's individual mandate
The most promising products in pharma's pipeline will compete in a landscape that increasingly rewards big risks and places an emphasis on novel mechanisms. That comes with a catch.
Publicis Groupe has named Alan Wexler as chief executive of Publicis.Sapient as Chip Register has chosen to retire at the end of the year.
FDA releases information on Exondys 51; Sanofi's dengue vaccine faces new restrictions; Kellyanne Conway named opioid czar
Alex Azar, previously a senior executive at Eli Lilly, proposed granting Part B the authority to negotiate lower prices.
U.K. to be first to sell OTC Viagra; Regeneron offers startup scientific expertise; docs more likely to get poor marks when they reject patient requests
How worried should the industry's other major players be?
Company enlists Patti LaBelle to increase awareness for the pneumococcal pneumonia vaccine
FDA plans new guidance to bring complex generics to market more quickly; BioMarin sells priority review voucher for $125 million; Takeda expects Zika clinical trial results next year
The FDA's Office of Prescription Drug Promotion issued a warning letter to Amherst Pharmaceuticals and Magna Pharmaceutical.
Facebook has formally outlined is advertising policies to its users but the industry feels the internet giant is offloading responsibility instead of stepping up.
Teva to cut thousands of U.S. jobs; Regeneron drops Eylea combo drug development; insurers, drugstores, and hospitals increasingly teaming up
The CEO's experience launching medical reference app Epocrates led him to found a social network for physicians.
WebMD reportedly lays off 10% of workforce; Roche blocks Herceptin biosimilar with patent suit; insurers cover Collegium's Xtampza over Purdue's OxyContin
J&J to hold meeting on maintaining Remicade market share; Acorda ends development of Parkinson's drug; Darzalex notches positive first-line results
Emmy-nominated Maia Samuel becomes executive director of expanded Haymarket Content Lab; Bernadette Casey promoted to executive director of Haymarket Content Hub.
Marketers survey the pluses and minuses of the platform's new 280-character limit.
The FDA approves EpiPen competitor Auvi-Q for small children; pharma executives are warm up to Amazon; Purdue approached states about opioid-epidemic settlement
FDA approves Genentech's hemophilia drug; former Insys CEO pleads not guilty to bribery charges; federal jury rules in favor of Endo in Testim lawsuit
Docs biased against research from poor countries, study finds; Astellas probed over patient-assistance charity support; Acorda reports deaths in Parkinson's trial
Lions Health still stands as a separate two-day event, despite a sweeping revamp of the Cannes Lions festival, disappointing some who decried its lack of full integration within the larger program.
French holding company Publicis has welcomed the raft of changes announced to the Cannes Lions festival Monday, while others have given it a more cautious welcome.
FDA approves AstraZeneca asthma drug; Senate tax reform bill would repeal Obamacare mandate; J&J drops Remicade biosimilar lawsuit
Ketchum, Ogilvy, Porter Novelli, Weber Shandwick, and FleishmanHillard are among the firms that have been awarded past Centers for Medicare and Medicaid Services IDIQ accounts.
Celebrities such as Angela Bassett and Mike Golic share their personal experiences about diabetes.
FDA approves first digital pill; biotech companies race to develop cancer-fighting microbiome drugs; Loxo and Bayer reach $1.55 billion deal for rare cancer drugs
Dynavax receives FDA approval for hepatitis-B vaccine; Novartis strikes R&D deal with gene-editing startup; White House nominates new HHS head
W2O's Windy City office has added three health and analytics leaders over the past six months.
Get America Covered is working to encourage consumers to sign up for coverage through the Affordable Care Act.
AstraZeneca sales fall on generic competition; Anthem broadens access for Duchenne muscular dystrophy drug; researchers are developing new biopsy techniques
GSK hires Google biotech exec to lead R&D; Merck gets FDA-approval for CMV therapy; ex-Lilly exec reportedly top HHS secretary pick
Ty Curran, previously CEO of the sister agencies, will serve as chairman in 2018.
Pharmacy benefit managers are increasingly measuring a patient's outcome in the context of adherence.
FDA to change Risk Evaluation Mitigation Strategies to prevent delayed generic approvals; Ohio rejects drug-price measure; Aetna CEO wants to improve in-person pharmacy experience
A mini wave of state-level rule-making has thrust the issue of restrictions on pharma payments to medical professionals back into the spotlight.
Senator investigates Alkermes' opioid-marketing tactics; FDA approves Roche cancer drugs; CVS to launch next-day delivery nationwide
The CDC has launched the first wave of its awareness campaign about prescription opioids.
Midway through Campaign's audience with Publicis Groupe's Maurice Lévy, a heavily French-accented voice exclaims, "Now it is time for the real boss to arrive."
Valeant sells Addyi back to Sprout; some advertisers halt business with Outcome Health; Amgen cuts R&D jobs
In April, a month or so after brands were accused of funding terrorist videos on YouTube, Procter & Gamble cut down the number of sites its ads ran on by 69%.
The blogger talks the challenges of influencer marketing in healthcare, chronic disease, and big brand activations.
Experimental Gilead and GSK HIV drugs are expected to compete; GSK R&D head resigns; Valeant subsidiary scores eye-drug approval
Teva reports lower-than-expected Q3 earnings; BI and Dicerna partner in NASH drug development; AstraZeneca's experimental asthma drug fails in Phase-III